Frontlight ResearchEarly access
Childhood cancers trials in France
207 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2/3Taking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Bayonne, Bordeaux, Boulogne-Billancourt, Grenoble Cedex 9, Lille, Marseille, Nice, Paris Cedex 18, Pierre-Bénite, Rouen Cedex, Saint-Herblain Cedex, Strasbourg
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - Phase 1/2Active, not recruitingA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Where
- Bordeaux, Lyon, Marseille, Nantes, Paris, Villejuif
- Age
- 1 month to 17 years
- People
- 50 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00 - Phase 1Taking peopleA Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Where
- Bordeaux, Paris
- Age
- 6 months to 17 years
- People
- 18 worldwide
- Run by
- AbbVie
See details and how to joinNCT07306832 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Bordeaux, Clermont-Ferrand, Lyon, Nîmes, Saint-Herblain, Strasbourg, Toulouse, Vandœuvre-lès-Nancy, Villejuif
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 1/2Taking peopleA Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
- Where
- Bordeaux, Lyon, Villejuif
- People
- 64 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07602777 - Phase 1/2Not yet taking people in FrancePhase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.
- Where
- Bordeaux, Lille, Lyon, Marseille, Nancy, Paris, Strasbourg, Toulouse
- Age
- 6 years to 40 years
- People
- 89
- Run by
- University Hospital, Strasbourg, France
See details and how to joinNCT07853105 - No phaseTaking peopleStudy for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation
- Where
- Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille, Lyon, Marseille, Montpellier, Nantes, Nice, Paris, Rennes, Rouen, Saint-Priest-en-Jarez, Sèvres, Strasbourg, Toulouse, Tours, Vandœuvre-lès-Nancy
- People
- 150
- Run by
- Institut Claudius Regaud
See details and how to joinNCT05983991 - Phase 2Taking peopleImmunotherapy Master Trial for Advanced Cancers
- Where
- Villejuif
- Age
- 12 years and over
- People
- 275
- Run by
- UNICANCER
See details and how to joinNCT07431073 - Phase 3Not yet taking people in FranceSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
- Where
- Angers, Besançon, Bordeaux, Bron, Dijon, La Tronche, Le Kremlin-Bicêtre, Lille, Marseille, Montpellier, Nancy, Paris, Reims, Rennes, Strasbourg, Toulouse
- Age
- 12 years to 17 years
- People
- 50
- Run by
- University Hospital, Angers
See details and how to joinNCT07845994 · EU 2024-511114-20-00 - No phaseTaking peopleA Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
- Where
- Toulouse
- People
- 170 worldwide
- Run by
- Chiesi Farmaceutici S.p.A.
See details and how to joinNCT06423573 - Phase 1/2Active, not recruitingA Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Where
- Angers, Bordeaux, Lyon, Marseille, Villejuif
- Age
- Up to 25 years
- People
- 75 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT04094610 · EU 2023-506464-14-00 - Phase 1/2Taking peopleA Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Where
- Lyon, Nantes, TOULOUSE, Villejuif
- Age
- 12 years and over
- People
- 359 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00 - Phase 2Taking peopleA Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
- Where
- Bordeaux, Lille, Lyon, Montpellier, Nantes, Nice, Paris, Rennes, Strasbourg Cedex 2, Toulouse Cedex 9, Vandoeuvre lès Nancy
- Age
- 1 year to 17 years
- People
- 100 worldwide
- Run by
- Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00 - No phaseTaking peopleEffect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer
- Where
- Bordeaux
- Age
- 15 years to 49 years
- People
- 70
- Run by
- Institut Bergonié
See details and how to joinNCT07614620 - Phase 2Taking peopleLong-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
- Where
- Lille, Montpellier Cedex 5, Paris, Pessac, Pierre-Bénite, Rennes
- People
- 1,500 worldwide
- Run by
- Kite, A Gilead Company
See details and how to joinNCT05041309 · EU 2023-507041-28-00 - Phase 2Not yet taking people in FranceRoll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
- Where
- Dijon, Montpellier Cedex 5, Paris
- People
- 51 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07679269 · EU 2026-525890-38-00 - Phase 1/2Taking peopleA Phase 1/2 study of Enzomenib (DSP-5336) in Patients with Acute leukemia
- Where
- Angers Cedex 9, Bobigny Cedex, Le Mans Cedex 9, Lille Cedex, Limoges, Marseille, Nantes, Nice, Nimes Cedex 9, Paris, Pessac Cedex, Pierre-Bénite, Toulouse Cedex 9, Villejuif
- People
- 94 worldwide
- Run by
- Sumitomo Pharma America Inc.
See details and how to join2022-502741-10-00 - No phaseNot yet taking people in FranceEffectiveness of a Visual Telerehabilitation Program on Visual Perception in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour
- Where
- Strasbourg
- Age
- 10 years to 40 years
- People
- 120 worldwide
- Run by
- Institut National de la Santé Et de la Recherche Médicale, France
See details and how to joinNCT07558395 - Phase 3Taking peopleAn international trial for children with atypical teratoid/rhabdoid tumours (ATRT)
- Where
- Angers, Lyon, Marseille, Paris, Rennes, Strasbourg Cedex 2, Villejuif
- Age
- Up to 17 years
- People
- 301 worldwide
- Run by
- GPOH gGmbH
See details and how to join2022-501456-28-00 - No phaseTaking peopleMoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
- Where
- Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille, Limoges, Lyon, Marseille, Montpellier, Nantes, Nice, Paris, Poitiers, Reims, Rennes, Rouen, Saint-Denis, Saint-Etienne, Strasbourg, Toulouse, Tours, Vandœuvre-lès-Nancy
- Age
- 6 years to 25 years
- People
- 1,800
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT05691608 - Phase 1/2Taking peopleCombination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
- Where
- Angers, Bordeaux, Bordeaux Cedex, Bron, Lille, Lille Cedex, Lyon, Marseille, Paris, Toulouse, Villejuif
- Age
- 12 years and over
- People
- 70
- Run by
- Centre Leon Berard
See details and how to joinNCT07243470 · EU 2023-510568-11-00 - Phase 3Taking peopleStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Where
- Bordeaux, Bron, Clichy, Lyon Cedex 03, Marseille, Montpellier Cedex 5, Nantes, Pessac, Pierre-Bénite, Talence, Toulouse
- Age
- 12 years to 100 years
- People
- 240 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00 - No phaseTaking peopleContribution of 3D Modeling in Surgical Management of Pediatric Retroperitoneal and Pelvic Tumors
- Where
- Paris
- Age
- 3 months to 17 years
- People
- 40
- Run by
- Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT06418243 - Phase 1Taking peoplePhase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Where
- Lyon, Villejuif
- Age
- 12 years to 85 years
- People
- 411 worldwide
- Run by
- Inhibrx Biosciences, Inc
See details and how to joinNCT03715933 · EU 2023-508139-29-00 - Phase 3Taking peopleSIOP RANDOMET 2017
- Where
- Amiens Cedex 1, Angers, Besançon Cedex, Bordeaux, Brest, Caen Cedex 9, Clermont-Ferrand, Dijon, Grenoble Cedex 9, Lille, Limoges, Lyon, Marseille, Montpellier, Nantes, Nice, Paris, Poitiers, Reims, Rennes, Rouen Cedex, Saint-Denis, St Etienne Cedex 2, Strasbourg Cedex 2, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy, Villejuif
- Age
- Up to 17 years
- People
- 409 worldwide
- Run by
- GPOH gGmbH
See details and how to join2023-508926-91-00